SILVER SPRING
Fasenra cleared for Hypereosinophilic Syndrome
- Sponsor
- AstraZeneca $AZN
- Drug
- Fasenra · benralizumab
- Indication
- Hypereosinophilic Syndrome
FDA approved AstraZeneca's Fasenra for adult and pediatric patients aged 12+ with hypereosinophilic syndrome without an identifiable non-hematologic cause.
What this means
Fasenra is an antibody treatment that targets a protein receptor involved in eosinophil production, reducing high levels of these immune cells that can cause tissue damage. Today FDA approved Fasenra for hypereosinophilic syndrome, a rare condition where excess eosinophils lead to inflammation and organ problems. This decision expands treatment options for patients aged 12 and older who have this condition without a known underlying cause.
Drug Watch — recent news on Fasenra
- CDSCO Approves AstraZeneca's Fasenra for Hypereosinophilic Syndrome in India - Medical Dialogues
- Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication - TradingView
- AstraZeneca Pharma Receives CDSCO Approval to Import and Sell Benralizumab for HES Patients Aged 12+ - Sahi
- Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study - The Lancet
- The Fasenra auto-injector. AstraZeneca brings severe asthma treatment home for US patients - ad-hoc-news.de
Sponsor Watch — recent news on AstraZeneca
- Cathie Wood Just Bet Big on This Biotech Stock
- Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
- MSD wins FDA approval for cholesterol pill to help plug Keytruda void
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill